Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.

Lubet RA, Szabo E, Iwata KK, Gill SC, Tucker C, Bode A, Steele VE, Juliana MM, Nicastro HL, Grubbs CJ.

Cancer Prev Res (Phila). 2013 May;6(5):448-54. doi: 10.1158/1940-6207.CAPR-12-0322. Epub 2013 Mar 26.

2.

Pursuit of personalized anticancer therapy: leveraging collaboration between academia and the biotech/pharmaceutical industry.

Buck E, Mulvihill M, Iwata KK.

Mt Sinai J Med. 2010 Jul-Aug;77(4):358-65. doi: 10.1002/msj.20195. Review.

PMID:
20687181
3.

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.

Guttman-Yassky E, Mita A, De Jonge M, Matthews L, McCarthy S, Iwata KK, Verweij J, Rowinsky EK, Krueger JG.

Eur J Cancer. 2010 Jul;46(11):2010-9. doi: 10.1016/j.ejca.2010.04.028. Epub 2010 Jun 2.

PMID:
20621734
4.

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.

Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS.

Cancer Res. 2008 Oct 15;68(20):8322-32. doi: 10.1158/0008-5472.CAN-07-6720.

5.

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.

Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, Eyzaguirre A, Rosenfeld-Franklin M, Gibson NW, Miglarese M, Epstein D, Iwata KK, Haley JD.

Clin Exp Metastasis. 2008;25(6):685-93. doi: 10.1007/s10585-007-9121-7. Epub 2008 Jan 31. Review.

6.

Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.

Zerbe LK, Dwyer-Nield LD, Fritz JM, Redente EF, Shroyer RJ, Conklin E, Kane S, Tucker C, Eckhardt SG, Gustafson DL, Iwata KK, Malkinson AM.

Cancer Chemother Pharmacol. 2008 Sep;62(4):605-20. Epub 2007 Nov 21.

PMID:
18030469
7.

Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer.

Javle MM, Gibbs JF, Iwata KK, Pak Y, Rutledge P, Yu J, Black JD, Tan D, Khoury T.

Ann Surg Oncol. 2007 Dec;14(12):3527-33. Epub 2007 Sep 19.

PMID:
17879119
8.

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.

Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P, Haley JD.

Mol Cancer Ther. 2007 Feb;6(2):532-41.

9.

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.

Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.

Mol Cancer Ther. 2006 Nov;5(11):2676-84.

11.

Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model.

Jin Y, Iwata KK, Belldegrun A, Figlin R, Pantuck A, Zhang ZF, Lieberman R, Rao J.

Mol Cancer Ther. 2006 Jul;5(7):1754-63.

12.

Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.

Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N, Haley JD.

Cancer Res. 2005 Oct 15;65(20):9455-62.

13.

Novel application of layered expression scanning for proteomic profiling of plucked hair follicles.

Traicoff JL, Baibakov G, Biesecker G, Richardson F, Ramesh A, Galperin MM, Iwata KK, Knezevic V.

Dermatology. 2005;210(4):273-8.

PMID:
15942212
14.
15.

Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.

Petty WJ, Dragnev KH, Memoli VA, Ma Y, Desai NB, Biddle A, Davis TH, Nugent WC, Memoli N, Hamilton M, Iwata KK, Rigas JR, Dmitrovsky E.

Clin Cancer Res. 2004 Nov 15;10(22):7547-54.

16.

The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.

Barbacci EG, Pustilnik LR, Rossi AM, Emerson E, Miller PE, Boscoe BP, Cox ED, Iwata KK, Jani JP, Provoncha K, Kath JC, Liu Z, Moyer JD.

Cancer Res. 2003 Aug 1;63(15):4450-9.

17.

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata KK, Morin MJ.

J Pharmacol Exp Ther. 1999 Nov;291(2):739-48.

PMID:
10525095
18.

Identification and characterization of baxepsilon, a novel bax variant missing the BH2 and the transmembrane domains.

Shi B, Triebe D, Kajiji S, Iwata KK, Bruskin A, Mahajna J.

Biochem Biophys Res Commun. 1999 Jan 27;254(3):779-85.

PMID:
9920818
19.

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P.

Cancer Res. 1997 Nov 1;57(21):4838-48.

20.

Umbilical cord transforming growth factor-beta 3: isolation, comparison with recombinant TGF-beta 3 and cellular localization.

Stewart AA, Haley JD, Qu GY, Stam K, Fenyö D, Chait BT, Marshak DR, Ng AY, Marley G, Iwata KK.

Growth Factors. 1996;13(1-2):87-98.

PMID:
8962723
21.

Physical and biological characterization of a growth-inhibitory activity purified from the neuroepithelioma cell line A673.

Stam K, Stewart AA, Qu GY, Iwata KK, Fenyö D, Chait BT, Marshak DR, Haley JD.

Biochem J. 1995 Jan 1;305 ( Pt 1):87-92.

22.

Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3.

Sonis ST, Lindquist L, Van Vugt A, Stewart AA, Stam K, Qu GY, Iwata KK, Haley JD.

Cancer Res. 1994 Mar 1;54(5):1135-8.

23.
24.

Characterization of the binding of transforming growth factor-beta 1, -beta 2, and -beta 3 to recombinant beta 1-latency-associated peptide.

Miller DM, Ogawa Y, Iwata KK, ten Dijke P, Purchio AF, Soloff MS, Gentry LE.

Mol Endocrinol. 1992 May;6(5):694-702.

PMID:
1603080
25.

The effects of transforming growth factor beta 3 on the growth of highly enriched hematopoietic progenitor cells derived from normal human bone marrow and peripheral blood.

Strife A, Lambek C, Perez A, Darzynkiewicz Z, Skierski J, Gulati S, Haley JD, ten Dijke P, Iwata KK, Clarkson BD.

Cancer Res. 1991 Sep 15;51(18):4828-36.

26.

Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms.

Cheifetz S, Hernandez H, Laiho M, ten Dijke P, Iwata KK, Massagué J.

J Biol Chem. 1990 Nov 25;265(33):20533-8.

27.

Recombinant transforming growth factor type beta 3: biological activities and receptor-binding properties in isolated bone cells.

ten Dijke P, Iwata KK, Goddard C, Pieler C, Canalis E, McCarthy TL, Centrella M.

Mol Cell Biol. 1990 Sep;10(9):4473-9.

28.

Molecular characterization of transforming growth factor type beta 3.

ten Dijke P, Iwata KK, Thorikay M, Schwedes J, Stewart A, Pieler C.

Ann N Y Acad Sci. 1990;593:26-42. No abstract available.

PMID:
2375596
29.

Identification of another member of the transforming growth factor type beta gene family.

ten Dijke P, Hansen P, Iwata KK, Pieler C, Foulkes JG.

Proc Natl Acad Sci U S A. 1988 Jul;85(13):4715-9.

30.

Isolation of tumor cell growth-inhibiting factors from a human rhabdomyosarcoma cell line.

Iwata KK, Fryling CM, Knott WB, Todaro GJ.

Cancer Res. 1985 Jun;45(6):2689-94.

31.

Two distinct tumor cell growth-inhibiting factors from a human rhabdomyosarcoma cell line.

Fryling CM, Iwata KK, Johnson PA, Knott WB, Todaro GJ.

Cancer Res. 1985 Jun;45(6):2695-9.

32.

Photoreactive probes for high resolution mapping of membrane proteins.

Iwata KK, Manweiler CA, Bramhall J, Wisnieski BJ.

Prog Clin Biol Res. 1978;22:579-89.

PMID:
662918
33.

Effects of low temperature and lipid modification on the proliferation of cultured mammalian cells.

Williams RE, Rittenhouse HG, Iwata KK, Fox CF.

Exp Cell Res. 1977 Jun;107(1):95-104. No abstract available.

PMID:
558901
34.

Electron spin resonance evidence for vertical asymmetry in animal cell membranes.

Wisnieski BJ, Iwata KK.

Biochemistry. 1977 Apr 5;16(7):1321-6.

PMID:
191067
35.

Regulation of Glutamine Transport in Escherichia coli.

Willis RC, Iwata KK, Furlong CE.

J Bacteriol. 1975 Jun;122(3):1032-7.

Supplemental Content

Loading ...
Support Center